Ondine Demonstrates High Efficacy of Photodisinfection Technology Against Key Hospital Pathogen Pseudomonas aeruginosa



    VANCOUVER, Nov. 19 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM:
OBP) a medical technology company developing photodisinfection based products,
today announced the conclusion of a preclinical program demonstrating high
efficacy of its Photodisinfection technology against cultures and biofilms of
Pseudomonas aeruginosa, one of the most dangerous hospital-acquired pathogens.
This work provides important preclinical support for Ondine's
photodisinfection programs for skin wounds, burn and outer ear infections.
    "Our preclinical Pseudomonas program has evolved over the last two years,
focusing on optimization of many photodisinfection parameters including dosing
and formulation," said Dr. Nicolas Loebel, Chief Technology Officer, Ondine
Biopharma Corporation. "Pseudomonas is extremely difficult to kill and occurs
throughout hospital environments as an opportunistic pathogen. Our
photodisinfection system has demonstrated 100% eradication of Pseudomonas
aeruginosa in planktonic (free-floating) cultures, and in excess of 99.9%
kills in biofilms. The data from the preclinical research supports our belief
that our photodisinfection technology could provide significant benefits over
conventional antipseudomonal therapies such as topical antibiotics or
micronized silver.
    "Pseudomonas is a Gram-negative bacterium living in biofilm colonies
surrounded by a viscous alginate matrix, a protective strategy that works so
well that Pseudomonas has even been found living in hospital disinfectant
solutions. The bacterium is notorious for its resistance to antibiotics. The
case fatality rate in Pseudomonas-infected patients hospitalized with cancer,
cystic fibrosis, burns and wounds is as high as 50%. Our photodisinfection
technology has proven highly effective at disrupting Pseudomonas biofilms and
rapidly killing the causative bacteria in vitro. The eradication process does
not upregulate bacterial resistance factors because the process is rapid, the
kill rates are high, and killing occurs through disruption of surface
membranes rather than internal metabolic processes. After launching
Periowave(TM), our ground-breaking photodisinfection treatment for adult
periodontal disease, our new product development efforts are being focused
into nasal MRSA decolonization, disinfection of skin wounds and burns and
treatment of external ear infections. The combination of wide therapeutic
window, absence of resistance and treatment speed implies a potentially new
paradigm in the treatment of these complex infections."

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broadspectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release.





For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com; Irma
Gomez-Dib, Media & Investors Relations, FD International, (212) 850-5761,
Irma.gomez.dib@fd.com; Nominated Adviser, Neil Johnson, Ryan Gaffney,
Canaccord Adams Ltd, +44(0)20 7050 6500

Organization Profile

ONDINE BIOPHARMA CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890